This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
LivaNova (LIVN) Soars: Stock Adds 10.4% in Session
by Zacks Equity Research
LivaNova (LIVN) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Can Solid European Sales Boost Inogen (INGN) in Q2 Earnings?
by Zacks Equity Research
Strong performance in Europe is likely to boost Inogen's (INGN) top line in Q2. However, decline rental-revenues is a concern.
Integer Holdings (ITGR) Catches Eye: Stock Jumps 7.5%
by Zacks Equity Research
Integer Holdings (ITGR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Here's Why You Should Add Inogen (INGN) to Your Portfolio
by Zacks Equity Research
Inogen's (INGN) solid product portfolio is a key catalyst. Also, the company benefits from strong focus in Europe.
Zacks.com featured highlights include: Johnson Outdoors, Home, Inogen, Blucora and Weight Watchers
by Zacks Equity Research
Zacks.com featured highlights include: Johnson Outdoors, Home, Inogen, Blucora and Weight Watchers
5 Profitable Stocks to Scoop Up Spectacular Returns
by Zacks Equity Research
Profitability analysis is one of the best tools to evaluate the future movement of a stock.
Stryker or Baxter: Which is a Better Pick for Your Portfolio?
by Zacks Equity Research
Stryker (SYK) and Baxter's (BAX) strong expected growth rates and rising share price make them close contenders in the MedTech industry.
Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for XHE
Inogen (INGN) Beats Q1 Earnings Estimates, Lifts 2018 View
by Zacks Equity Research
Inogen (INGN) rides on strong domestic and international sales growth in Q1; a raised guidance buoys optimism.
What's in the Cards for Inogen (INGN) This Earnings Season?
by Zacks Equity Research
Inherent benefits of POCs, direct-to-customer business model, underpenetrated international markets and expanding product portfolio are key growth catalysts for Inogen (INGN) in Q1.
Why Is Inogen (INGN) Down 7% Since its Last Earnings Report?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Inogen (INGN) reports impressive Q4 financial results on the back of strong business-to-business and direct-to-consumer sales growth.
Healthcare, Vertex to Drive 3D Systems (DDD) Q4 Earnings?
by Zacks Equity Research
Strong prospects in 3D Systems' (DDD) healthcare business and Vertex brand are likely to prove conductive to its profitability in the to-be-reported quarter.
Is a Beat in Store for Inogen (INGN) This Earnings Season?
by Zacks Equity Research
Strong product portfolio and a unique direct-to-consumer business model are expected to drive Inogen (INGN) in Q4.
Inogen (INGN) Gains on Diverse Product Line, Competition Rife
by Zacks Equity Research
Inogen (INGN) rides on POC growth. Existing market challenges likely to mar prospects.
Can CVG Boost Medtronic's (MDT) Q3 Earnings Once Again?
by Zacks Equity Research
New therapies within CVG should help Medtronic???s (MDT) Q3 gain traction in the rapidly growing markets for LVAD, TAVR, drug-coated balloons, atrial fibrillation and insertable diagnostics.
Inogen Rides on Solid Product Portfolio Amid Forex Woes
by Zacks Equity Research
Inogen's (INGN) expanding product portfolio is a key catalyst. Foreign exchange headwinds continue to hurt the company's growth trajectory.
Inogen Claims Top Position in Deloitte List on Solid Growth
by Zacks Equity Research
Inogen's (INGN) unique direct-to-customer business model has lent it a leading position in the United States.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Inogen's (INGN) stellar third-quarter numbers benefit from direct-to-consumer sales and lower cost of goods sold per unit.
McKesson (MCK) to Acquire RxCrossroads for $735 Million
by Zacks Equity Research
McKesson's (MCK) acquisition of RxCrossroads will boost its Specialty Health business.
Inogen (INGN) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Inogen (INGN) develops, manufactures and markets POCs. The company's direct-to-customer business model lent it a leading position in the oxygen therapy space.
Inogen (INGN) Down 2.4% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Inogen (INGN) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights: SP Plus, Inogen, Graco, Sterling Construction and FireEye
by Zacks Equity Research
Zacks.com featured highlights: SP Plus, Inogen, Graco, Sterling Construction and FireEye
5 Stocks to Beat the Market This Reporting Cycle
by Zacks Equity Research
Inside the stocks that are likely to beat earnings estimates in their upcoming releases.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
Inogen (INGN) delivers better-than-expected results in Q2 with significant contributions from the Business-to-Business segment. Moreover, raised guidance buoys optimism.